PRESS RELEASE: Basilea Announces Submission Of Marketing Authorization Application for Ceftobiprole

Basilea Announces Submission Of Marketing Authorization Application for Ceftobiprole By Janssen-Cilag AG To Swiss Regulatory Authority

Basel, Switzerland, Aug 23, 2007 - Basel, Switzerland, August 23, 2007 - Basilea Pharmaceutica Ltd. (SWX:BSLN) announced today the submission of a marketing authorization application for ceftobiprole to Swissmedic by its license partner Janssen-Cilag AG, a Johnson & Johnson company. This submission is for the use of ceftobiprole in the treatment of complicated skin and soft tissue infections (cSSTI) including diabetic foot infections.

Swissmedic had previously granted accelerated assessment of the marketing authorization application ("Beschleunigtes Zulassungsverfahren") for ceftobiprole for the treatment of complicated skin and soft tissue infections.

Ceftobiprole is currently under review by regulatory authorities in the U.S., Canada and in the European Union.

Ceftobiprole is being developed through an exclusive worldwide collaboration between Basilea Pharmaceutica Ltd. and Cilag GmbH International.

About Basilea

Basilea Pharmaceutica Ltd. is an integrated biopharmaceutical company headquartered in Basel, Switzerland, and listed on the SWX Swiss Exchange (SWX:BSLN). Basilea is currently focused on the development of new antibacterial, antifungal and dermatology drugs.


This communication is intended for information to the financial community only (investors and/or potential investors and their advisors) and expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.